NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 352)
Posted On: 10/23/2018 4:13:37 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Discusses New Subsidiaries, Intellectual Property in Interview on Uptick Newswire’s Stock Day Podcast
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a drug delivery platform innovator that has developed and out-licenses its disruptive delivery technology, was recently featured on Uptick Newswire’s Stock Day Podcast. Chairman of the Board and CEO Chris Bunka provided an update regarding Lexaria’s licenses and technology. “Lexaria has been somewhat of a pioneer in this aspect of the business. We have been beating the drum on intellectual property since we began in 2014,” Bunka stated in the interview. “We now have over 50 patents outstanding in over 40 countries around the world. Our IP suite is one of the biggest and strongest in the industry.” Bunka also discussed the company’s four new subsidiaries with specific focuses on pharmaceutical, hemp, nicotine and cannabis. “Each one of our subsidiary companies has been empowered through exclusive licensing arraignments with our parent company to be able to offer our broad intellectual property suite to their respective customers,” Lexaria Chairman of the Board and CEO Chris Bunka stated in the interview.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a drug delivery platform innovator that has developed and out-licenses its disruptive delivery technology, was recently featured on Uptick Newswire’s Stock Day Podcast. Chairman of the Board and CEO Chris Bunka provided an update regarding Lexaria’s licenses and technology. “Lexaria has been somewhat of a pioneer in this aspect of the business. We have been beating the drum on intellectual property since we began in 2014,” Bunka stated in the interview. “We now have over 50 patents outstanding in over 40 countries around the world. Our IP suite is one of the biggest and strongest in the industry.” Bunka also discussed the company’s four new subsidiaries with specific focuses on pharmaceutical, hemp, nicotine and cannabis. “Each one of our subsidiary companies has been empowered through exclusive licensing arraignments with our parent company to be able to offer our broad intellectual property suite to their respective customers,” Lexaria Chairman of the Board and CEO Chris Bunka stated in the interview.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼